AngioDynamics (NASDAQ:ANGO) was downgraded by research analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a report released on Tuesday.

Other research analysts have also issued reports about the stock. Zacks Investment Research raised shares of AngioDynamics from a “sell” rating to a “hold” rating in a report on Tuesday, September 11th. Canaccord Genuity reissued a “hold” rating and set a $20.00 target price on shares of AngioDynamics in a research note on Thursday, July 12th. Finally, Raymond James lowered shares of AngioDynamics from an “outperform” rating to a “market perform” rating in a research note on Wednesday, July 11th. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $18.44.

NASDAQ ANGO opened at $19.97 on Tuesday. AngioDynamics has a one year low of $15.16 and a one year high of $24.49. The company has a quick ratio of 1.55, a current ratio of 2.64 and a debt-to-equity ratio of 0.16. The stock has a market capitalization of $806.02 million, a PE ratio of 27.50 and a beta of 0.86.

AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings results on Thursday, September 27th. The medical instruments supplier reported $0.16 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.18 by ($0.02). AngioDynamics had a net margin of 4.62% and a return on equity of 5.44%. The business had revenue of $85.34 million during the quarter, compared to analyst estimates of $84.05 million. During the same period last year, the firm posted $0.13 earnings per share. The company’s quarterly revenue was down .1% on a year-over-year basis. Equities analysts forecast that AngioDynamics will post 0.85 EPS for the current year.

A number of institutional investors have recently bought and sold shares of the business. BlackRock Inc. boosted its stake in AngioDynamics by 7.3% during the 2nd quarter. BlackRock Inc. now owns 5,478,788 shares of the medical instruments supplier’s stock valued at $121,848,000 after purchasing an additional 374,834 shares during the period. Janus Henderson Group PLC boosted its stake in AngioDynamics by 0.3% during the 2nd quarter. Janus Henderson Group PLC now owns 1,802,894 shares of the medical instruments supplier’s stock valued at $40,096,000 after purchasing an additional 6,027 shares during the period. Northern Trust Corp boosted its stake in AngioDynamics by 0.8% during the 2nd quarter. Northern Trust Corp now owns 1,209,647 shares of the medical instruments supplier’s stock valued at $26,903,000 after purchasing an additional 9,119 shares during the period. JPMorgan Chase & Co. boosted its stake in AngioDynamics by 958.2% during the 1st quarter. JPMorgan Chase & Co. now owns 895,414 shares of the medical instruments supplier’s stock valued at $15,447,000 after purchasing an additional 810,794 shares during the period. Finally, Segall Bryant & Hamill LLC boosted its stake in AngioDynamics by 18.1% during the 2nd quarter. Segall Bryant & Hamill LLC now owns 769,732 shares of the medical instruments supplier’s stock valued at $17,119,000 after purchasing an additional 117,950 shares during the period. 98.17% of the stock is owned by hedge funds and other institutional investors.

About AngioDynamics

AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

Read More: Buyback

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.